Wednesday, July 26, 2017 10:10:58 AM
“The company anticipates filing an investigational device exemption (IDE) supplement to add an interim efficacy readout in the fourth quarter of 2018 and expects top line data in the fourth quarter of 2019.”
Tweet this
The investigational CardiAMP cell therapy system is designed to deliver a high dose of a patient’s own bone marrow cells directly to the region of cardiac dysfunction to stimulate the body’s natural healing mechanism after a heart attack. Patients are selected for the investigational treatment, in part, based on biomarkers in their bone marrow that are anticipated to maximize the potential for patient benefit.
“Leading clinical sites are actively screening patients for the randomized phase of our Phase III trial, and we are onboarding additional clinical sites in the United States,” stated BioCardia Chief Medical Officer Eric Duckers, MD, PhD, FESC. “The company anticipates filing an investigational device exemption (IDE) supplement to add an interim efficacy readout in the fourth quarter of 2018 and expects top line data in the fourth quarter of 2019.”
The CardiAMP Heart Failure Trial is a Phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at 40 centers nationwide, which includes a 10-patient roll-in cohort. The trial’s primary endpoint is an improvement in six minute walking distance at 12 months post-treatment. In addition, the primary endpoint analysis incorporates the impact of major adverse cardiac events and other clinically meaningful events.
The company reaffirms guidance on its IDE submission in calendar year 2017 for a new CardiAMP indication to treat patients post-myocardial infarction. In addition, the company anticipates submitting an investigational new drug (IND) application in calendar year 2018 for CardiALLO cell therapy, which utilizes bone marrow-derived mesenchymal cells from a donor to treat heart failure.
http://www.businesswire.com/news/home/20170726005489/en/BioCardia-Completes-Roll-in-Cohort-Pivotal-Phase-III
Recent BCDA News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:30:48 PM
- BioCardia Regains Full Compliance with Nasdaq Listing Requirements • GlobeNewswire Inc. • 09/18/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:06:56 PM
- BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/09/2024 08:05:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/06/2024 11:45:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 04:42:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 04:41:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 04:40:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 04:40:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 10:01:22 AM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/30/2024 09:21:22 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 08/30/2024 09:20:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/30/2024 12:00:10 PM
- BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 08/30/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/30/2024 04:15:13 AM
- Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)] • Edgar (US Regulatory) • 08/30/2024 12:09:56 AM
- BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family • GlobeNewswire Inc. • 08/29/2024 12:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/29/2024 10:02:51 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 09:12:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 11:00:31 AM
- FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 08/13/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:06:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 05:57:35 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM